(Chief Medical Advisor, dual board-certified Obesity Medicine/Internal Medicine)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomized, double-blind, double-dummy, placebo-controlled, phase 3 trial
Vergura, R
A study published in Obesity Reviews found that these medications could help reduce the frequency of binge eating episodes in individuals with BED by promoting feelings of fullness and reducing the urge to overeat (Erlanson-Albertsson et al., 2015)
It just gets smaller and smaller until the amount is pharmacologically irrelevant
As the 3 mg liraglutide product is approved for chronic weight management, it seems reasonable for patients to continue therapy until they have lost 5 to 10% of their baseline body weight and potentially longer if there is evidence of further and/or durable weight loss associated with treatment